Is amitriptyline appropriate for treating restless‑leg syndrome in a 49‑year‑old woman with seizures who is taking levetiracetam (Keppra), vitamin D, and hydroxyzine?

Amitriptyline Should Not Be Used for Restless Legs Syndrome

Correct—amitriptyline is not appropriate for treating restless legs syndrome (RLS) and may actually worsen the condition. While amitriptyline is not specifically addressed in the most recent 2025 American Academy of Sleep Medicine (AASM) guidelines for RLS treatment, the available evidence indicates it can induce or exacerbate RLS symptoms and increase periodic limb movements during sleep.

Why Amitriptyline Is Contraindicated

Evidence of Harm

Amitriptyline has been documented to:

• Induce or worsen RLS symptoms in case reports and pharmacovigilance databases 1, 2
• Increase periodic limb movements (PLM) during sleep in controlled studies—a randomized, double-blind trial showed 75 mg amitriptyline significantly increased PLM per hour compared to placebo in healthy subjects 3
• Appear in French pharmacovigilance data as a suspected drug in RLS adverse drug reactions (reporting odds ratio 15.9) 2

Mechanism of Action

As a tricyclic antidepressant with serotonergic properties, amitriptyline falls into the category of medications that should be discontinued when possible in RLS patients. The 2026 JAMA review explicitly states that "medications associated with RLS, including serotonergic antidepressants...should be discontinued" 4.

Specific Concerns for This Patient

Seizure Considerations

This 49-year-old woman is already taking levetiracetam (Keppra) for seizures. Importantly:

• RLS is more common in patients with epilepsy (particularly those with refractory epilepsy and nocturnal seizures) 5
• There is no contraindication between levetiracetam and appropriate RLS treatments
• Levetiracetam itself is not associated with causing or worsening RLS

Hydroxyzine Concern

Critical caveat: The patient is currently taking hydroxyzine, which is a centrally acting H1 antihistamine. This medication can exacerbate RLS and should be discontinued if possible 4. This may be contributing to her RLS symptoms.

Recommended Treatment Approach

First-Line Management

1. Check iron status immediately: Obtain serum ferritin and transferrin saturation

   • If ferritin ≤100 ng/mL or transferrin saturation <20%, start ferrous sulfate 325-650 mg daily or every other day 6, 4
   • Consider IV iron (ferric carboxymaltose 1000 mg) for faster response 6

2. Discontinue exacerbating medications:

   • Stop hydroxyzine (centrally acting antihistamine) 4
   • Avoid amitriptyline entirely

Pharmacologic Treatment

If medication is needed after addressing iron and discontinuing hydroxyzine:

First-line: Gabapentinoids (strong recommendation, moderate certainty) 6

• Gabapentin: Start 300 mg at bedtime, titrate up to 1200-1800 mg/day divided doses
• Pregabalin: Start 75 mg at bedtime, titrate to 150-300 mg/day
• Approximately 70% of patients achieve much or very much improved symptoms vs 40% with placebo 4
• Safe with levetiracetam—no significant drug interactions

Second-line options if gabapentinoids fail:

• Extended-release oxycodone or other low-dose opioids (conditional recommendation, moderate certainty) 6
• Dipyridamole (conditional recommendation, low certainty) 6

Medications to Avoid

The 2025 AASM guidelines specifically recommend against these agents [@1-8@]:

• Dopamine agonists (pramipexole, ropinirole, rotigotine) as standard therapy—7-10% annual risk of augmentation
• Bupropion (despite some older data suggesting benefit)
• Carbamazepine
• Clonazepam
• Valproic acid
• Cabergoline (strong recommendation against) 6

Clinical Pitfalls

1. Don't assume antidepressants are safe for RLS: Serotonergic antidepressants, including tricyclics like amitriptyline, can worsen RLS 4, 7

2. Bupropion paradox: While one small study suggested bupropion might reduce RLS symptoms 7, the 2025 AASM guidelines recommend against its use (conditional recommendation, moderate certainty) 6. Follow the guideline.

3. Antihistamine trap: Over-the-counter sleep aids containing diphenhydramine or hydroxyzine can significantly worsen RLS and should be avoided 4

4. Quality of life impact: RLS significantly impairs quality of life in patients with epilepsy in both physical and mental domains 5—aggressive treatment is warranted

Bottom line: Amitriptyline should be avoided entirely in this patient. Start with iron supplementation if indicated, discontinue hydroxyzine, and use gabapentin or pregabalin as first-line pharmacologic therapy if needed.